Kodiak Sciences Inc (KOD) Stock Price, Quote & News

Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degenerati...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 281 0850

Website: kodiak.com

Address:

1200 Page Mill Road, Palo Alto, United States

biomaster22 Jun. 17 at 12:00 PM

$KOD can't seem to break out of this see saw 3.50 - 4.25 and back as we get coser to 2026 readouts we should be rewarded from here !

0 · Reply

Stekli27 Jun. 15 at 3:24 PM

$KOD After-hours move looks nice — maybe it’s finally time for the rumors to start doing their job. There’s been increasing talk that small batches were run successfully at Lonza, and that validation at Ursus could be done. If that’s the case, then we might be a lot closer to a BLA announcement than many assume. Still under the radar… for now. 🧬🔥

0 · Reply

StormChaser Jun. 13 at 11:28 PM

$KOD wut news? Haha

1 · Reply

Stekli27 Jun. 13 at 7:42 PM

$KOD is set to follow $KZIA 🚀 — it’s just a matter of time. It’ll happen when nobody expects it, maybe even overnight. We could see a double. The real question is: July? August? Or am I just dreaming? 😉

1 · Reply

Stekli27 Jun. 10 at 3:33 PM

$NRSN and $KOD my two black horses that have potential to get myself closer to retirement 😤😛

0 · Reply

AidenB Jun. 6 at 7:37 PM

$KOD can someone remind me what is the next step for wAMD. Is trial going again. Or what exactly happened and what do we expect? Can't find detils on thier website.

1 · Reply

rasmushenriksson Jun. 6 at 1:35 AM

$OCUL Anyone remember $KOD , a "one-trick pony" in the wAMD space. Reached mcap of $8B before Phase 3 readout. Those holding $OCUL might be in for a ride...

3 · Reply

Stekli27 Jun. 4 at 5:38 PM

$KOD One of the last chances to buy this stock at such a low price before tomorrow's presentation at Jefferies. 😎

0 · Reply

Quantum_Capital_LLC Jun. 3 at 3:23 AM

$KOD Have been hovering around current price for the last 7/8 days. There's a break coming soon and with technical indicators currently trending down, it could be bad for owners if it happens sooner rather than later. If it can hold on for a while longer technical indicators may reverse to the upside. If break happens near end of week or next week then we could see a good run up. Add to near term watch list.

1 · Reply

Kelly12 Jun. 2 at 11:20 AM

$KOD news?

1 · Reply

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 14, 2025, 4:15 PM EDT - 5 weeks ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 1, 2025, 11:43 PM EDT - 7 weeks ago

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

Mar 27, 2025, 4:01 PM EDT - 3 months ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 4:39 PM EDT - 3 months ago

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Feb 23, 2025, 8:08 PM EST - 4 months ago

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Feb 4, 2025, 7:30 AM EST - 4 months ago

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Jan 7, 2025, 6:00 AM EST - 5 months ago

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 12:33 PM EST - 6 months ago

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Nov 14, 2024, 4:01 PM EST - 7 months ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 11, 2024, 6:15 AM EST - 7 months ago

Kodiak Sciences to Participate in Upcoming Investor Conferences

Oct 14, 2024, 5:35 PM EDT - 8 months ago

Kodiak Sciences to Present at Innovate Retina 2024

Sep 23, 2024, 6:00 AM EDT - 9 months ago

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Sep 17, 2024, 4:05 PM EDT - 9 months ago

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Aug 14, 2024, 4:01 PM EDT - 11 months ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

May 29, 2024, 4:36 PM EDT - 1 year ago

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

May 15, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 13, 2024, 7:32 PM EDT - 1 year ago

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

May 2, 2024, 4:30 PM EDT - 1 year ago

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Mar 28, 2024, 8:57 PM EDT - 1 year ago

Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 6:30 AM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Mar 26, 2024, 6:15 AM EDT - 1 year ago

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Jan 30, 2024, 6:30 AM EST - 1 year ago

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Jan 4, 2024, 4:15 PM EST - 1 year ago

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:15 PM EST - 1 year ago

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:01 PM EST - 1 year ago

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 6, 2023, 5:00 AM EST - 1 year ago

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

Nov 1, 2023, 11:21 PM EDT - 1 year ago

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

Oct 11, 2023, 6:00 AM EDT - 1 year ago

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

Sep 8, 2023, 6:00 AM EDT - 1 year ago

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 7, 2023, 6:00 AM EDT - 1 year ago

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Aug 14, 2023, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

Jul 24, 2023, 6:38 AM EDT - 2 years ago

Kodiak Sciences scraps development of eye disorder drug

Jul 24, 2023, 6:36 AM EDT - 2 years ago

Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatment

Jul 24, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

May 30, 2023, 4:15 PM EDT - 2 years ago

Kodiak Sciences to Present at Upcoming Investor Conferences

May 15, 2023, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

Apr 21, 2023, 7:30 AM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

Apr 3, 2023, 7:30 AM EDT - 2 years ago

Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases

Mar 28, 2023, 4:08 PM EDT - 2 years ago

Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Feb 9, 2023, 7:30 AM EST - 2 years ago

Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting

Jan 4, 2023, 7:00 AM EST - 2 years ago

Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 16, 2022, 4:30 PM EST - 2 years ago

Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference

Nov 14, 2022, 1:17 PM EST - 2 years ago

Kodiak: Turnaround Strategy Has Shown Life Thus Far

Nov 9, 2022, 4:01 PM EST - 2 years ago

Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights

Sep 7, 2022, 4:05 PM EDT - 3 years ago

Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference

Aug 18, 2022, 5:47 PM EDT - 3 years ago

Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)

Aug 9, 2022, 4:33 PM EDT - 3 years ago

Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights

Aug 8, 2022, 1:58 PM EDT - 3 years ago

Kodiak Sciences: All Eyes For A Sentiment Turnaround After Positive Beacon Results

biomaster22 Jun. 17 at 12:00 PM

$KOD can't seem to break out of this see saw 3.50 - 4.25 and back as we get coser to 2026 readouts we should be rewarded from here !

0 · Reply

Stekli27 Jun. 15 at 3:24 PM

0 · Reply

StormChaser Jun. 13 at 11:28 PM

$KOD wut news? Haha

1 · Reply

Stekli27 Jun. 13 at 7:42 PM

1 · Reply

Stekli27 Jun. 10 at 3:33 PM

$NRSN and $KOD my two black horses that have potential to get myself closer to retirement 😤😛

0 · Reply

AidenB Jun. 6 at 7:37 PM

$KOD can someone remind me what is the next step for wAMD. Is trial going again. Or what exactly happened and what do we expect? Can't find detils on thier website.

1 · Reply

rasmushenriksson Jun. 6 at 1:35 AM

$OCUL Anyone remember $KOD , a "one-trick pony" in the wAMD space. Reached mcap of $8B before Phase 3 readout. Those holding $OCUL might be in for a ride...

3 · Reply

Stekli27 Jun. 4 at 5:38 PM

$KOD One of the last chances to buy this stock at such a low price before tomorrow's presentation at Jefferies. 😎

0 · Reply

Quantum_Capital_LLC Jun. 3 at 3:23 AM

1 · Reply

Kelly12 Jun. 2 at 11:20 AM

$KOD news?

1 · Reply

AnomalyDetective May. 24 at 2:56 PM

$KOD mda signal broke down May 6th with large net outflows continuing for now. Check for latest signal. https://top.vmbreakouts.com/kod-30-picked-apr-21st/

0 · Reply

Stekli27 May. 22 at 4:29 PM

$KOD today back to 4.50 direction 😇

0 · Reply

Rrrr007 May. 20 at 8:52 PM

$SAVA $KOD $NKTR $ANRO 15%UP In one day! Not too late though

0 · Reply

Stekli27 May. 20 at 7:58 PM

$KOD It's very volatile at the moment, but the momentum is here. The market will likely react gradually to incoming news in July. There’s speculation that PPQ could be close to completion. If confirmed, it could give the stock a boost—but let's wait to see what the company announces 🚀

0 · Reply

AidenB May. 20 at 6:05 PM

$KOD 7 possibly achievable by EOW

1 · Reply

AidenB May. 20 at 3:58 PM

$KOD going to 7, 70 and possibly 140. 7 sooner than you can imagine

1 · Reply

Rrrr007 May. 17 at 1:23 PM

$SAVA $KOD $NKTR ANRO🚀🚀🚀👇 Phase 2 proof-of-concept trials remain on track: Topline data expected from ALTO-203 in MDD in the second quarter🔥 of 2025 followed by ALTO-101 in schizophrenia in the second half 🔥of 2025 – Late-stage programs advancing: Topline data expected from the Phase 2b trial of ALTO-300 in MDD in mid-2026 followed by the Phase 2b trial of ALTO-100 in bipolar depression in the second half of 2026 – New data presented at recent scientific conferences support Alto’s biomarker-driven pipeline and patient stratification approach – Strong cash position of approximately $161.3 million expected to fund planned operations into 2028!!! and through at least four upcoming clinical study readouts –

0 · Reply

_www_larval_com_ May. 15 at 5:02 PM

$KOD just reverted 5% higher to -20% (~513Kv) moments ago, 05/16 options, follow for more volatility.

0 · Reply

tahloolaaa May. 15 at 4:57 PM

$KOD what was the market expecting, a unicorn to fall from the sky?

0 · Reply

ZacksResearch May. 15 at 2:08 PM

$KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans. See full results here: https://www.zacks.com/stock/news/2471963/kodiak-q1-loss-wider-than-expected-pipeline-development-in-focus?cid=sm-stocktwits-2-2471963-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2471963_TEASER

0 · Reply

Webullbro May. 15 at 12:42 AM

$KOD Shares of Eastman Kodak Company (KODK - Free Report) have declined 7.1% since reporting results for the first quarter of 2025. This compares with the S&P 500 index’s 3.1% growth over the same time frame. Over the past month, the stock has lost 1.5% compared with the S&P 500’s 8.1% rally. Earnings & Revenue Performances

0 · Reply

DonCorleone77 May. 14 at 8:23 PM

$KOD Kodiak Sciences reports Q1 EPS ($1.09), consensus (87c) "In the first quarter of 2025, we maintained a strong focus on execution. We look forward to sharing our progress at an Investor R&D Update scheduled for July 16, 2025 at 1:00pm Eastern Time. We aim to demonstrate that our vision for Kodiak 2.0 as a precommercial stage retina focused biotech company with a maturing portfolio of three promising Phase 3 assets on track for topline data in 2026 is well-supported by our science and our progress on execution," said Victor Perlroth, M.D., Chairman and Chief Executive Officer of Kodiak Sciences. Kodiak ended the first quarter of 2025 with $138.9M of cash and cash equivalents. "We believe that our current cash will support our current and planned operations into 2026."

0 · Reply

Market Cap	186.26M
Revenue (ttm)	0.00
Net Income (ttm)	-176.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	244,200
Avg Vol	409,592
Day's Range	N/A - N/A
Shares Out	52.76M
Stochastic %K	19%
Beta	2.27
Analysts	Hold
Price Target	$6.80